Code intelligence

FDA-NDA207356 reimbursement alerts

Policy changes, MAC LCD updates, and CMS guidance referencing code FDA-NDA207356.

Critical code risk

Signal breakdown

1 shown · 1 total in platform

Risk: Critical

Critical

100%

High

Routine

Low

New this month

alerts added in last 30 days

Effective soon

—

no upcoming deadlines

FDA Approval: ARIKAYCE (AMIKACIN) — Type 3 - New Dosage Form

Policy FDA-NDA207356 · Pulmonology

Critical

Arikayce (amikacin liposomal inhalation suspension) received FDA approval in September 2018 as an inhaled orphan drug for refractory Mycobacterium avium complex (MAC) lung disease, administered via a

View alert